Venous thromboembolism has the same risk factors as atherosclerosis
A PRISMA-compliant systematic review and meta-analysis

Yuhong Mi, MMa, Shufeng Yan, MMa, Yanhui Lu, MD, PhDa, Ying Liang, MMa, Chunsheng Li, MDa,b,*

Abstract
Background: Previous studies have shown that idiopathic pulmonary embolism is positively associated with other cardiovascular events, such as myocardial infarction and stroke, suggesting a potentially important association between atherosclerosis risk factors and venous thromboembolism (VTE). We performed a meta-analysis to evaluate the correlation between risk factors for atherosclerosis and VTE.

Methods: In December 2014, we searched MEDLINE and EMBASE for studies evaluating the associations between VTE and risk factors for atherosclerosis and pooled outcome data using random-effects meta-analysis. In addition, we analyzed publication bias.

Results: Thirty-three case-control and cohort studies with a total of 185,124 patients met the inclusion criteria. We found that participants with body mass index (BMI) ≥30 kg/m² had a significantly higher prevalence of VTE than those with BMI <30 kg/m² in both case-control studies (odds ratio [OR] = 2.45, 95% confidence interval [CI]: 1.78–3.35) and cohort studies (relative risk [RR] = 2.39, 95% CI: 1.79–3.17). VTE was more prevalent in patients with hypertension than without hypertension (OR = 1.40, 95% CI: 1.06–1.84; RR = 1.36, 95% CI: 1.11–1.67). The findings were similar for VTE prevalence between patients with and without diabetes (OR = 1.78, 95% CI: 1.17–2.69; RR = 1.41, 95% CI: 1.20–1.66). Current smoking was significantly associated with VTE prevalence in case-control studies (OR = 1.34, 95% CI: 1.01–1.77), but in cohort studies (RR = 1.29, 95% CI: 0.96–1.72). In addition, we found that total cholesterol and triglyceride concentrations were significantly higher in patients with VTE than without VTE (weighted mean differences [WMD] = 8.94 mg/dL, 95% CI: 3.52–14.35 mg/dL, and WMD = 14.00 mg/dL, 95% CI: 8.85–19.16 mg/dL, respectively). High-density lipoprotein cholesterol concentrations were significantly lower in patients with VTE than without VTE (WMD = −2.03 mg/dL, 95% CI: −3.42 to −0.63 mg/dL). Higher quality studies were more homogeneous, but confirmed the same significant associations.

Conclusions: Based on our systematic review and meta-analysis, we observed a significant association between VTE and the risk factors for atherosclerosis. These results may make an important contribution to clinical practice regarding VTE treatment.

Abbreviations: BMI = body mass index, CI = confidence interval, DVT = deep venous thrombosis, HDL-C = high-density lipoprotein cholesterol, OR = odds ratio, PE = pulmonary embolism, PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-Analyses, RR = relative risk, TC = total cholesterol, TG = triglyceride, VTE = venous thromboembolism, WMD = weighted mean differences.

Keywords: atherosclerosis, risk factors, venous thromboembolism

1. Introduction

Venous thromboembolism (VTE), which comprises pulmonary embolism (PE) and deep venous thrombosis (DVT), is common, and requires early diagnosis and treatment because of its association with high mortality and morbidity.[1,2] Even though Virchow’s triad of factors contributing to thrombosis—vascular endothelial damage, hypercoagulation, and venous stasis—has been widely known for many years,[3] the role of PE as one of the leading causes of death is complex, multifactorial, and interactive. Venous and arterial thrombotic disorders have long been considered separate pathophysiological states, arterial thrombosis originating from platelet activation, and VTE from coagulation factors. However, the concept that VTE and atherosclerosis are 2 entirely distinct entities has recently been challenged.[4] Studies have shown that idiopathic PE (20%) is associated with other cardiovascular events such as myocardial infarction and stroke.[5] Furthermore, some studies have demonstrated a potential association between VTE and atherosclerosis.[6–7] Some studies have also shown that these 2 vascular complications share multiple risk factors such as age, obesity, smoking, diabetes mellitus, blood hypertension, dyslipidemia, and metabolic syndrome.[8] A 20-year cohort study has shown that patients with DVT and PE have a substantially increased risk of...
myocardial infarction and stroke during the first year after the thrombotic event, whereas some studies have reported negative results for some risk factors. Because there is still controversy about the relationship between VTE and risk factors for atherosclerosis, the most recent meta-analysis on this topic was published in 2008, and several large case-control and prospective cohort studies have been reported since then, we performed a systematic review of published reports and a meta-analysis to update and reassess the strength of the evidence concerning risk factors for atherosclerosis and VTE. Clear evidence for an association between VTE and traditionally high risk factors for atherosclerosis and VTE. However, some studies have reported negative results for some risk factors such as age, sex, BMI, diabetes mellitus, hypertension, and smoking (Table 2).

2. Methods

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement was followed in our study. Ethical approval was not necessary for our meta-analysis because all included studies were reviewed based on text key words. Then, the abstracts of suitable titles and full-text conforms to the abstracts were included. First search, titles alone were reviewed based on text key words. Then, the abstracts of suitable titles and full-text conforms to the abstracts were obtained and reviewed. We extracted the data from the suitable full-text reports as described in the following section. Parts of additional suitable reports in our study were supplemented when discovered by citation tracking.

2.1. Data sources and search strategy

A systematic search was performed on December 29, 2014 by searching PubMed from 1974 to December 2014 and EMBASE (OvidSP) from 1980 to December 2014. The detail of search strategy was shown in Table 1. For the first search, titles alone were reviewed based on text key words. Then, the abstracts of suitable titles and full-text conforms to the abstracts were obtained and reviewed. We extracted the data from the suitable full-text reports as described in the following section. Parts of additional suitable reports in our study were supplemented when discovered by citation tracking.

2.2. Study selection

All published studies that evaluated the prevalence or severity of atherosclerosis risk factors in patients with VTE and met the following criteria were included: English language articles; age from childhood to adulthood; prospective studies that recruited patients who had been diagnosed with VTE and included definitions of hypertension, dyslipidemia, hypercholesterolemia, and hypertriglyceridemia; concentrations of high-density lipoprotein cholesterol (HDL-C); body mass index (BMI); and the presence or absence of diabetes mellitus. In the selected studies, VTE (deep vein thrombosis and/or PE) had been diagnosed by at least one of the following standard means: Doppler echocardiography, deep lower limb compression ultrasonography, Doppler venous ultrasound or venography, computed tomography pulmonary angiography, and radioisotope studies such as pulmonary ventilation-perfusion scans. For atherosclerosis, outcomes that were reported for coronary arteriosclerotic cardiopathy, myocardial infarction, angina, acute coronary syndrome, or coronary disease were included.

All studies in which the entire cohort of patients with VTE had a concomitant, known, major risk factor (e.g., studies of patients undergoing major surgery or trauma, involving pregnant women only, patients with antiphospholipid antibody syndrome) were excluded.

2.3. Data extraction and quality assessment

References were screened and data extracted independently by 2 authors using a predetermined data collection template. In the case of disagreement about inclusion of studies and interpretation of data, a third investigator was consulted and consensus reached by discussion. The following data were recorded: publication characteristics, location of study, inclusion and exclusion criteria, sample size, and patients’ characteristics. The following risk factors for atherosclerosis were collected from each included study: number and proportion of patients, BMI, blood pressure, cholesterol or triglyceride (TG) concentrations, HDL-C concentrations, diabetes mellitus, and smoking. If information on the proportion of patients with and without a particular risk factor was not available, mean levels and standard deviations were extracted for both cases and controls.

The quality of all included studies was assessed using a scoring system that resulted in total scores for each study from 0 to 5 points (the highest quality was defined as 5 for cohort studies or 4 for case-control studies). In the system we created, one point is allocated for each of the following items: appropriate inclusion and exclusion criteria; adequately reported methodology for measuring risk factors; sample size >500; follow-up duration >3 years; and adjustments made for risk factors such as age, sex, BMI, diabetes mellitus, hypertension, and smoking (Table 2).

2.4. Data synthesis and analysis

Pooled odds ratio (OR), relative risk (RR) or weighted mean difference (WMD), and 95% confidence interval (CI) were calculated using the DerSimonian-Laird random-effects model, which takes study heterogeneity into account to generate the

Table 1

| Search Strategy: Searching MEDLINE and EMBASE (OvidSP) on December 25, 2014. |
|----------------------------------------|
| 1. PubMed from 1974 to December 2014   |
| ("thromboembolism" OR "venous thrombosis" OR "venous thromboembolism" OR "pulmonary embolism" OR “pulmonary thromboembolism” OR “pulmonary emboli” OR “deep-vein thrombosis”) AND (“atherosclerosis” OR “coronary arteriosclerotic cardiopathy” OR “angiina” OR “coronary disease” OR “myocardial infarction” OR “acute coronary syndrome”) AND (“hypertension” OR “dyslipidemia” OR “hyperlipopidemia” OR “hyperlipemia” OR “hypercholesterolemia” OR “cholesteroll” OR “hypertriglyceridemia” OR “tryglicerid” OR “high density lipoprotein” OR “high density lipoproteincholesterol” OR “density lipoprotein” OR “triglyceride” OR “overweight” OR “obesity” OR “overweight” OR “metabolic syndrome” OR “blood pressure” OR “diabetes” OR “diabetes mellitus” OR “hyperglycemia” OR “impaired glucose tolerance” OR “cigarette smoking” OR “smoking”) NOT (“Infant” OR “neonborn” OR “fetus”) |
| 2. PubMed from 1974 to December 2014 ("thromboembolism" OR “venous thrombosis” OR “venous thromboembolism” OR “pulmonary embolism” OR “pulmonary thromboembolism” OR “pulmonary emboli” OR “deep-vein thrombosis”) AND (“atherosclerosis” OR “coronary arteriosclerotic cardiopathy” OR “coronary disease” OR “myocardial infarction” OR “acute coronary syndrome”) AND (“hypertension” OR “dyslipidemia” OR “hyperlipopidemia” OR “hyperlipemia” OR “hypercholesterolemia” OR “cholesteroll” OR “hypertriglyceridemia” OR “tryglicerid” OR “high density lipoprotein” OR “high density lipoproteincholesterol” OR “density lipoprotein” OR “triglyceride” OR “overweight” OR “obesity” OR “overweight” OR “metabolic syndrome” OR “blood pressure” OR “diabetes” OR “diabetes mellitus” OR “hyperglycemia” OR “impaired glucose tolerance” OR “cigarette smoking” OR “smoking”) NOT (“Infant” OR “neonborn” OR “fetus”) |
estimates. The extent of variability across studies attributable to heterogeneity beyond chance was estimated using the I² statistic.[46] Meta-analyses were stratified by study design. Potential publication bias was assessed with the Egger test and is presented graphically by funnel plots of the natural log of the OR, RR, or WMD versus its standard error.[47] STATA 11 (Stata, College Station, TX) was used for statistical computations. A 2-sided $P < 0.05$ was considered significant. Sensitivity analyses were based on the quality of the studies to assess the robustness of our primary results.

### 3. Results

Figure 1 shows the process for selecting reports. Of 3490 reports selected in the initial search by scanning titles and abstracts, 48 seemed to meet the inclusion criteria. These were selected for detailed assessment, which resulted in exclusion of a further 15 studies for the following reasons: 3, no comparable data[2,48,49]; 4, no control group[50–53]; 2, only autopsies[54,55]; 2, no objective criteria for diagnoses[56–58]; and 3, duplicate data.[24,30,59] Finally, 33 studies with a total of 185,124 patients[6,10–12,17–45] were included in this meta-analysis. Relevant characteristics of these 33 studies are shown in Table 3. The number of subjects per study ranged between 86 and 26,185.[29,41] The mean age of participants varied widely from study to study because of the varied inclusion criteria, which ranged from children with diabetes mellitus only[45] to adults with various risk factors depending on the studies’ inclusion criteria. Seven studies investigated only women[17,19,21,22,30,31,33] and 2 studies investigated only men.[20,34] There were 10 prospective cohort studies[10–12,20,30,32,38,40,41,44] with durations of follow-up ranging from 5.6[30] to 26 years.[20] Twenty-three case-control studies included healthy subjects.[6,17–19,21–29,31,33–37,39,42,43,45] Two studies included only patients with DVT.[18,26] Three of the 33 studies identified no associations between VTE and risk factors for atherosclerosis; these were all cohort studies.[10,32,44] It was not possible to compare the prevalence of cardiovascular risk factors between patients with unprovoked and provoked VTE because there were too few studies for which this information was available.

### 3.1. Association between BMI and VTE

In this meta-analysis, 10 case-control studies and 4 cohort studies with 19,608 patients with thrombosis and 68,521 controls...
### Table 3
Characteristics of Included Trials in This Meta-Analysis.

| Study                      | Sample Size, n | Year | Age (y) | Sex (Women%) | Study Design   | Risk Factors in Each Study                  |
|----------------------------|----------------|------|---------|--------------|----------------|-------------------------------------------|
| Poulter et al[17]          | 4141           | 1995 | 20–44   | 100          | Case-control   | Diabetes, smoking, hypertension           |
| Kawasaki et al[18]         | 218            | 1997 | 49      | 51           | Case-control   | TC, TG                                    |
| Holbraaten et al[19]       | 528            | 1999 | 59      | 100          | Case-control   | Diabetes, smoking, hypertension           |
| Hansson et al[20]          | 851            | 1999 | >50     | 0            | Prospective cohort | Smoking, hypertension                      |
| McCol et al[21]            | 160            | 2000 | <51     | 100          | Case-control   | TC, TG, HDL-C                             |
| Nightingale et al[22]      | 1728           | 2000 | 15–49   | 100          | Case-control   | BMI, smoking, hypertension                 |
| Segui et al[23]            | 283            | 2000 | 42      | 40           | Case-control   | TC, TG                                   |
| Vayá et al[24]             | 537            | 2002 | 42      | 62           | Case-control   | BMI, TC, TG                               |
| Tsai et al[25]             | 21,680         | 2002 | >45     | 55           | Prospective cohort | BMI, diabetes, hypertension, TC, TG    |
| Lidegaard et al[26]        | 5041           | 2002 | 15–44   | 100          | Case-control   | BMI, diabetes, smoking, hypertension       |
| Abdollahi et al[27]        | 908            | 2003 | 45      | 58           | Case-control   | BMI                                       |
| González-Ordóñez et al[28] | 251            | 2003 | 62      | 51           | Case-control   | BMI, TC, HDL-C                            |
| Paganin et al[29]          | 138            | 2003 | 51      | 51           | Case-control   | BMI                                       |
| Frondini et al[30]         | 203            | 2003 | 66      | 54           | Case-control   | BMI, diabetes, smoking, hypertension       |
| Zamani et al[31]           | 86             | 2003 | 46      | 56           | Case-control   | TC, TG                                   |
| Cushman et al[32]          | 16,608         | 2004 | 50–79   | 100          | Prospective cohort | Diabetes, smoking                          |
| Doggen et al[33]           | 2413           | 2004 | 70      | 100          | Case-control   | TC, TG, HDL-C                             |
| Frederiksen et al[34]      | 7864           | 2004 | 48      | 57           | Prospective cohort | Diabetes, smoking, hypertension, TC, TG, HDL-C |
| Sydney et al[35]           | 942            | 2004 | 15–44   | 100          | Case-control   | BMI, smoking                               |
| Deguchi et al[36]          | 198            | 2005 | <55     | 0            | Case-control   | Diabetes, smoking, hypertension, TC, TG, HDL-C |
| Vayá et al[37]             | 534            | 2007 | 42±12   | 47           | Case-control   | BMI, hypertension, TC, TG                 |
| Pomp et al[28]             | 8889           | 2008 | 25–66   | 54           | Case-control   | Smoking                                   |
| Hermandes et al[39]        | 558            | 2009 | 57      | 56           | Case-control   | Diabetes                                   |
| Holst et al[40]            | 18,954         | 2010 | >20     | 54           | Prospective cohort | BMI, diabetes, smoking, hypertension, T, C, TG, HDL-C |
| Delluc et al[41]           | 934            | 2012 | >18 (58–80) | 59  | Case-control   | Diabetes, TC, TG, HDL-C                   |
| Watansakul et al[42]       | 15,340         | 2012 | 54      | 55           | Prospective cohort | BMI, diabetes, smoking, hypertension, TC, TG, HDL-C |
| van Schouwenburg et al[43] | 7627           | 2012 | 28–75   | 51           | Prospective cohort | Smoking                                   |
| Enge et al[44]             | 11,302         | 2012 | 25–96   | 55           | Prospective cohort | Diabetes, smoking, hypertension, TC, TG, HDL-C |
| Brakkan et al (Tromsø Study)[45] | 26,185     | 2012 | ≥25    | 53           | Prospective cohort | BMI, hypertension, TC, TG, HDL-C       |
| Delluc et al[46]           | 1171           | 2013 | 73      | 57           | Case-control   | BMI                                       |
| Bell et al[47]             | 12,298         | 2013 | 45–64   | 50           | Case-control   | Diabetes                                   |
| Lennard et al (Tromsø study)[48] | 16,165   | 2014 | ≥25 (25–87) | 47 | Prospective cohort | Diabetes                                   |
| Tala et al[49]             | 789            | 2014 | <16     | 58           | Prospective cohort | Diabetes                                   |

BMI = body mass index, HDL-C = high-density lipoprotein cholesterol, TC = total cholesterol, TG = triglyceride.
included data on BMI. As shown in Figure 2, participants with BMI ≥ 30 kg/m² had a significantly higher prevalence of VTE than those with BMI < 30 kg/m² in both case-control (OR = 2.45, 95% CI: 1.78–3.35, I² = 79.7%) and cohort studies (RR = 2.39, 95% CI: 1.79–3.17, I² = 72.7%). When lower quality case-control studies were excluded, the 5 remaining high-quality case-control studies[22,25,26,33,42] still reported a significant difference between these 2 BMI categories (OR = 2.43, 95% CI: 1.72–3.44, I² = 82.6%).

3.2. Association between diabetes and VTE

In this meta-analysis, 9 case-control and 6 cohort studies with 44,809 subjects with thrombosis and 83,207 controls included data on subjects with diabetes mellitus. As shown in Figure 3, the prevalence of VTE was significantly higher among participants with diabetes than those without diabetes (case-control studies: OR = 1.78, 95% CI: 1.17–2.69, I² = 66.4%; cohort studies: RR = 1.41, 95% CI: 1.20–1.66, I² = 0.0%). When lower quality case-control studies were excluded, the 6 remaining high-quality case-control studies[17,25,37,39,43,45] still showed a significant difference between participants with and without diabetes (OR = 1.99, 95% CI: 1.28–3.11, I² = 63.9%).

3.3. Association between hypertension and VTE

In this meta-analysis, 7 case-control and 6 cohort studies with 23,639 thrombosis patients and 74,249 controls included data on hypertension. Figure 4 shows that the prevalence of VTE was significantly higher among participants with hypertension than those without hypertension (case-control studies: OR = 1.40, 95% CI: 1.06–1.84, I² = 49.9%; cohort studies: RR = 1.36, 95% CI: 1.11–1.67, I² = 71.7%). When lower quality case-control studies were excluded, the 3 remaining high-quality case-control studies[17,22,25] still reported a significant difference between subjects with and without hypertension (OR = 1.70, 95% CI: 1.36–2.13, I² = 0.0%).

3.4. Association between current smoking and VTE

In this meta-analysis, 8 case-control and 6 cohort studies with 16,555 patients with thrombosis and 71,946 controls included
data on smoking. As shown in Figure 5, a significant association between current smoking and VTE prevalence was found in case-control studies (OR = 1.34, 95% CI: 1.01–1.77, I² = 87.1%), but not in cohort studies (RR = 1.29, 95% CI: 0.96–1.72, I² = 75.2%). When lower quality case-control studies were excluded, the 5 remaining high-quality case-control studies[^17,22,25,33,36] still showed a significant difference between current smokers and nonsmokers (OR = 1.48, 95% CI: 1.04–2.11, I² = 92.0%).

3.5. Association between total cholesterol and VTE

In this meta-analysis, 10 case-control and 6 cohort studies with 11,044 subjects with thrombosis and 79,974 controls included data on total cholesterol (TC) (Fig. 6). Overall, higher mean TC concentrations were reported in subjects with VTE than in those without VTE (WMD = 8.94 mg/dL, 95% CI: 3.52–14.35 mg/dL, I² = 95.2%). Subgroup analysis indicated that significantly higher TC concentrations among subjects with VTE were observed in cohort studies (WMD = 15.89 mg/dL, 95% CI: 10.33–21.44 mg/dL, I² = 95.0%), but not in case-control studies (WMD = 3.34 mg/dL, 95% CI: −7.16 to 13.85 mg/dL, I² = 92.5%). When lower quality case-control and cohort studies were excluded, the 2 remaining high-quality case-control[^31,39] and 6 cohort studies[^10–12,32,38,41] still showed a significant difference between subjects with and without high TC concentrations (WMD = 12.90, 95% CI: 7.13–18.66, I² = 96.0%).

3.6. Association between HDL-C and VTE

In this meta-analysis, 5 case-control and 4 cohort studies with 6,589 patients with thrombosis and 51,484 controls included data on HDL-C concentrations (Fig. 7). Mean HDL-C concentrations were significantly lower in subjects with VTE than in those without VTE (WMD = −2.03 mg/dL, 95% CI: −3.42 to −0.63 mg/dL, I² = 73.5%). Subgroup analysis showed that significantly lower HDL-C concentrations among VTE patients were observed in case-control studies (WMD = −1.95 mg/dL, 95% CI: −3.36 to −0.54 mg/dL, I² = 14.7%), but not in cohort studies (WMD = −1.91 mg/dL, 95% CI: −4.36 to 0.54 mg/dL, I² = 87.5%). When lower quality case-control and cohort studies were excluded, the
remaining 2 high-quality case-control[31,39] and 4 cohort studies[10,32,38,41] still showed a significant difference between subjects with and without high HDL-C concentrations (WMD = −1.75, 95% CI: −3.36 to −0.14, I² = 81.5%).

3.7. Association between TG and VTE

In this meta-analysis, 10 case-control and 5 cohort studies with 7200 subjects with thrombosis and 72,206 controls included data on TG concentrations (Fig. 8). A significantly higher mean TG concentration was reported among patients with VTE than in those without VTE (WMD = 14.00 mg/dL, 95% CI: 8.85–19.16 mg/dL, I² = 57.3%). Subgroup analysis indicated that the significantly higher TG concentrations among VTE patients were observed in both case-control (WMD = 19.32 mg/dL, 95% CI: 10.56–28.08 mg/dL, I² = 52.9%) and cohort studies (WMD = 7.42 mg/dL, 95% CI: 5.16–9.68 mg/dL, I² = 0.0%). When lower quality case-control and cohort studies were excluded, the 2 remaining high-quality case-control[31,39] and 5 cohort studies[10,11,32,38,41] still showed significantly higher mean TG concentrations in subjects with VTE than without VTE (WMD = 7.46, 95% CI: 5.26–9.65, I² = 0.0%).

3.8. Publication bias

There was no evidence of publication bias on the basis of either visual inspection of funnel plots (Supplementary Figures S1–S6, http://links.lww.com/MD/B179) or Egger test for associations between VTE and BMI, diabetes, hypertension, current smoking, TC, or HDL-C (all P > 0.05) (Supplementary Figures E1–E6). However, a funnel plot (Supplementary Figure S7, http://links.lww.com/MD/B179) and Egger test (Supplementary Figure E7) suggested the presence of publication bias for the association between VTE and TG (P = 0.020).

4. Discussion

4.1. Our principle finding and its possible underlying mechanism(s)

Our present meta-analysis demonstrated that the major risk factors for atherothrombotic disease are also significantly associated with VTE, which explains why atherosclerosis is an independent risk factor for VTE.[7] Among the traditionally recognized risk factors for atherosclerosis we evaluated, obesity, diabetes mellitus, hypertension, and hypercholesteremia and
hypertriglyceridemia in particular had clear positive correlations with VTE, whereas HDL-C concentrations had a clear negative correlation with VTE. We found a significant association between current smoking and VTE prevalence in case-control studies, but not in cohort studies; however, in the latter the pooled RR was close to reaching significance.

Obesity has consistently been identified as a common risk factor for both arterial and VTE. The risk of VTE in subjects with obesity was about 2.39 to 2.45 times higher than that in those with BMI <30 kg/m² in our meta-analysis. All 14 studies that provided BMI data verified that BMI was closely associated with the prevalence of VTE; the same result was also reported for the high-quality studies. Previous reports on the association between atherosclerotic risk factors and VTE have thus far been inconsistent.[11,20,32,47,60] Studies conducted by Fronek et al.[61] and Sugerman et al.[62] have shown that abdominal obesity is associated with increased intraabdominal pressure and reduced venous blood flow velocity, which may increase susceptibility to thrombosis. Moreover, other studies[63,64] have shown that visceral adipose tissue is highly active metabolically, releasing proinflammatory, proatherogenic, and prothrombotic substances that may contribute to thrombosis risk. According to one study, the biological mechanisms may be involved high concentrations of fibrinogen and some clotting factors, low-grade systemic inflammation, increased intra-abdominal pressure, and reduced venous return from the lower limbs.[65] However, whether obesity itself definitely increases the risk of VTE is uncertain because several risk factors such as pregnancy,[66–68] oral contraceptive use,[69] and hormone replacement therapy[70] may coexist with obesity in subjects with current and recurrent VTE.

Eight of the 15 studies about diabetes mellitus reported a positive association[6,11,17,19,30,37,43,45] with VTE, whereas 7 did not.[12,25,32,34,38,39,44] Our pooled analysis resulted in a weak correlation; however, 4 cohort studies did not identify an association between diabetes mellitus and VTE.[12,32,38,44] A possible explanation for this discrepancy is that risk factors often coexist in patients with VTE, for example, diabetes mellitus may be result from metabolic syndrome.[71] The causal relationship between hyperglycemia and VTE has been confirmed by several
studies, the main mechanisms for the causality possibly involving activated factor VII activity, the increased thrombin-antithrombin complexes, and soluble tissue factor.[72,73] Whereas, study did not find the direct biological relationship between hyperglycemia and the coagulation system.[74]

Consistent with our study, several case-control studies have demonstrated an association between concentrations of serum lipids such as TG, TC, and lipoprotein (a) and VTE.[31,34,75,76] However, a number of large prospective studies have failed to confirm such associations, failing to support a role for serum lipids in the pathogenesis of VTE.[10,27,41,49] Our study showed that VTE was indeed associated with dyslipidemia; however, a funnel plot and Egger test suggested the presence of publication bias for the association between VTE and TG. This may be

Figure 6. Meta-analysis of the effect of total cholesterol concentrations (mg/dL) on venous thromboembolism (based on 10 case-control and 6 cohort studies). Squares represent point estimates for effect size expressed as a WMD with the size proportional to the inverse variance of the estimate. Diamond represents pooled estimate. Lines represent 95% CIs. CI = confidence interval, WMD = weighted mean difference.

Figure 7. Meta-analysis of the effect of high-density lipoprotein cholesterol concentrations (mg/dL) on venous thromboembolism (based on 5 case-control and 4 cohort studies). Squares represent point estimates for effect size expressed as a WMD with the size proportional to the inverse variance of the estimate. Diamond represents pooled estimate. Lines represent 95% CIs. CI = confidence interval, WMD = weighted mean difference.
attributable to failure to publish studies with negative result or to other variables such as race and geographical region. Funnel figures, which only determine whether a graph is symmetrical, cannot conclusively identify publication bias. The negative association between HDL-C and the prevalence of VTE in our study indicates that HDL-C may play a protective role in regulating thrombosis.

In the early days of research into this topic,[60] hypertension was identified as a risk factor for PE in the Nurses’ Health Study; however, most more recent prospective studies have found no association between blood pressure and VTE.[11,20,38,49] In our study, 7 of the 13 articles providing data on hypertension reported a positive association between hypertension and VTE.6,11,17,24,32,34,38 However, one reported a positive association in men,11 only when combined with smoking and BMI $\geq 30 \text{ kg/m}^2$.38 In addition, one of these studies involved subjects using oral contraception.17 These findings suggest that patients with hypertension have a tendency to develop VTE when they also have other risk factors.

Daily smoking, regardless of duration and amount, was not found to be a risk factor in several studies.11,41,49 However, other studies have identified heavy cigarette smoking as a risk factor for VTE.20,36,39 In the current meta-analysis, smoking was positively correlated with VTE in 5 cohort studies12,20,32,34,40 and 2 case-control studies21,36 among the 14 studies in which smoking was assessed. Smoking is a well-established risk factor for atherosclerotic disease; however, its role as an independent risk factor or effect modifier for VTE remains controversial. Several prospective studies have reported that smoking is an independent risk factor.38 One possible explanation for these discrepancies is that some studies have not provided sufficiently detailed information, such as current smoking versus previous smoking status and differences between heavier and lighter smokers.

Current research suggests that the mechanisms by which smoking induces hypercoagulation may be associated with the reduced fibrinolysis, inflammation, and increased blood viscosity.77–79 One study has shown a correlation between VTE and higher plasma fibrinogen and factor VIII concentrations among smokers,109 and others have shown that fibrinogen concentration drops rapidly to a normal level after cessation of smoking.81,82 Yarnell and other authors have detected a positive relationship between the amount of current tobacco consumption and plasminogen activator inhibitor-1 concentration, which may also be related to VTE.78,83

In contrast with a previous report,114 we found in this meta-analysis that smoking and HDL-C were risk factors for VTE in case-control studies, whereas TC was a risk factor for VTE only in the cohort studies.

4.2. Clinical significance

Because VTE is associated with multiple interacting factors, to minimize their influences on each other we eliminated cases of VTE diagnosed on autopsy15 and the subjects with definite provoking factors such as joint replacement.[83,86] Despite this, a mechanistic link between VTE and the risk factors for atherosclerosis remains uncertain. Based on the current findings, we speculate that both vascular disorders are simultaneously triggered by biological stimuli responsible for activating coagulation and inflammatory pathways in both the arterial and venous systems (VTE and atherothrombosis share common risk factors and the common pathophysiological characteristics of inflammation, hypercoagulability, and endothelial injury). Meanwhile, it is reasonable to assume that adequate management of the risk factors for atherosclerosis would reduce the risk of VTE. Studies have shown that statins may be protective against
VTE.\textsuperscript{47,87,88} The obvious mechanism for such a protective effect is through improving lipid profiles; however, another possibility is that statins may directly affect endothelial function and thus have affected our different risk factors; we acknowledge that confounding may exist, which means that ORs for meta-analyses were adjusted for potential confounders in the present meta-analysis. We could not always incorporate all studies into the meta-analysis due to discrepancies in study characteristics. In the present meta-analysis, we could not accurately analyze the in nature of this association and whether VTE can be beneficial to patients through improving lipid profiles.

Our study has several potential limitations. First, we could not perform a sex-specific analysis because some variables were measured in only some of the studies and not in others for various reasons. Second, detailed information about VTE events was not always provided. Third, not all studies provided information on thrombophilia testing, making it difficult for us to distinguish the risk factors from hereditary thrombophilia. Fourth, some of the summarized estimations for the association between the risk factor and VTE were highly heterogeneous (I\textsuperscript{2}>70\%) across the included studies, which may have affected the reliability of our results. Because it was not possible to adjust or stratify for potential confounders in the present meta-analysis, we could not resolve the heterogeneity by meta-regression. Lastly, the pooled ORs were calculated on study level and not individual level data, which means that ORs for meta-analyses were adjusted for different risk factors; we acknowledge that confounding may therefore have affected our findings.

5. Conclusions
This systematic review and meta-analysis showed significant associations between VTE and risk factors for atherosclerosis. Higher quality studies are needed in the future to clarify the nature of this association and whether VTE can benefit from intervention of established risk factors.

References
[1] Horlander KT, Mannino DM, Leeper KV. Pulmonary embolism mortality in the United States, 1979–1998: an analysis using multiple-cause mortality data. Arch Intern Med 2003;163:1711–7.
[2] Goldhaber SZ, Elliott CG. Acute pulmonary embolism: part I: epidemiology, pathophysiology, and diagnosis. Circulation 2003;108: 2726–9.
[3] Brotman DJ, Deitcher SR, Lip GY, et al. Virchow’s triad revisited. South Med J 2004;97:213–4.
[4] Prandoni P. Venous and arterial thrombosis: two aspects of the same disease? Clin Epidemiol 2009;1:1–6.
[5] Becattini C, Agnelli G, Prandoni P, et al. A prospective study on cardiovascular events after acute pulmonary embolism. Eur Heart J 2003;26:77–83.
[6] Prandoni P, Bilora F, Marchiori A, et al. An association between atherosclerosis and venous thrombosis. N Engl J Med 2003;348: 1435–41.
[7] Hong C, Zha F, Du D, et al. Coronary artery calcification and risk factors for atherosclerosis in patients with venous thromboembolism. Atherosclerosis 2005;183:169–74.
[8] Becattini C, Vedovati MC, Ageno W, et al. Incidence of arterial cardiovascular events after venous thromboembolism: a systematic review and a meta-analysis. J Thromb Haemost 2010;8:891–7.
[9] Sørensen HT, Høvsgård P, Pedersen L, et al. Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. Lancet 2007;960: 1773–9.
[10] van Schoonhoven JM, Mahmoodi BK, Gansevoort RT, et al. Lipid level does not influence the risk of venous thromboembolism. Thromb Haemost 2012;108:923–9.
[11] Tsiak BW, Cashman M, Rosamond WD, et al. Cardiovascular risk factors and venous thromboembolism incidence: the Longitudinal Investigation of Thromboembolism Etiology. Arch Intern Med 2002;162:1182–9.
[12] Wattanakit K, Lutsey PL, Bell EJ, et al. Association between cardiovascular disease risk factors and occurrence of venous thromboembolism: a time-dependent analysis. Thorax Haemost 2012;108: 588–15.
[13] Parkin L, Sweetland S, Ballaall W, et al. Body mass index, surgery, and risk of venous thromboembolism in middle-aged women: a cohort study. Circulation 2012;125:897–904.
[14] Ageno W, Becattini C, Bright T, et al. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 2008;117:93–102.
[15] Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009;62:1006–12.
[16] Torbicik A, Perrier A, Konstantinides S, et al. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008;8:2776–815.
[17] Poulter NR, Meikir O, Chang CL, et al. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1993;346:1573–82.
[18] Kawasaki T, Kambayashi J, Arisyini H, et al. Hypercoagulability as a risk factor for deep-vein thrombosis. Thorax Res 1997;86:67–73.
[19] Hoibraaten E, Abdelnoor M, Sandset PM. Hormone replacement therapy with estradiol and risk of venous thromboembolism: a population-based case-control study. Thorax Haemost 1999;8: 1218–21.
[20] Hansson PO, Eriksson H, Welin L, et al. Smoking and abdominal obesity: risk factors for venous thromboembolism among middle-aged men: “the Study of Men Born in 1913”. Arch Intern Med 1999;159: 1386–90.
[21] McColl MD, Sattar N, Ellison J, et al. Lipoprotein (a), cholesterol and triglycerides in women with venous thromboembolism. Blood Coagul Fibrinolysis 2000;11:225–9.
[22] Nightingale AL, Lawson RW, Simpson EL, et al. The effects of age, body mass index, smoking and general health on the risk of venous thromboembolism in users of combined oral contraceptives. Eur J Contracept Reprod Health Care 2000;5:265–74.
[23] Segui R, Estelles A, Mira Y, et al. PAF-1 promoter 4G/5G genotype as an additional risk factor for venous thrombosis in subjects with genetic thrombophilic defects. Br J Haematol 2000;111:122–8.
[24] Vayá A, Mira Y, Ferrando F, et al. Hyperlipidaemia and venous thromboembolism in patients lacking thrombophilic risk factors. Br J Haematol 2002;118:235–9.
[25] Lidegaard Ø, Edstrom B, Kreiner S. Oral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception 2002;65:187–96.
[26] Abdollahi M, Cashman M, Rosendaal FR. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost 2003;89:493–8.
[27] González-Ordoñez AJ, Fernández-Carreira JM, Fernández-Alvarez CR, et al. The concentrations of soluble vascular cell adhesion molecule-1 and lipids are independently associated with venous thromboembolism. Haematologica 2003;88:1035–43.
[28] Paganin F, Bourdeau A, Yyn JL, et al. Venous thromboembolism in passengers following a 12-h flight: a case-control study. Aviat Space Environ Med 2003;74:1277–80.
[29] Zamani A, Omrani GR, Lankarazi KB. Hyperhomocysteinemia, hyperlipidemia and risk of venous thromboembolism in Shiraz. East Mediterr Health J 2003;9:935–43.
[30] Cushman M, Kuller LH, Prentice R, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004;292:1573–9.
[31] Doggen CJ, Smith NL, Lemaire RN, et al. Serum lipid levels and the risk of venous thrombosis. Arterioscler Thromb Vasc Biol 2004;24:1970–5.
[32] Frederiksen J, Juhl K, Grande P, et al. Methyleneetrahydrofolic acid reductase polymorphism (C677T), hyperhomocysteinemia, and risk of ischemic cardiovascular disease and venous thromboembolism: prospective and casecontrol studies from the Copenhagen City Heart Study. Blood 2004;104:3046–51.
[33] Seguí R, Estellés A, Mira Y, et al. PAI-1 promoter 4G/5G genotype as an additional risk factor for venous thrombosis in subjects with genetic thrombophilic defects. Br J Haematol 2000;111:122–8.
[34] Vayá A, Mira Y, Ferrando F, et al. Hyperlipidemia and venous thromboembolism in women with venous thromboembolism. Blood Coagul Fibrinolysis 2000;11:225–9.
[35] Vázquez A, Calfó C, Simó M, et al. Influence of lipids and obesity on haemostatic and lipid parameters in patients with deep vein thrombosis. Thromb Haemost 2007;98:621–6.

[36] Hermanides J, Gobe DM, Devries JH, et al. Venous thrombosis is associated with hyperglycemia at diagnosis: a case-control study. J Thromb Haemost 2009;7:945–9.

[37] Holst AG, Jensen G, Prescott E. Risk factors for venous thromboembolism: results from the Copenhagen City Heart study. Circulation 2010;121:1896–903.

[38] Pomp ER, Rosendaal FR, Doggen CJ. Smoking increases the risk of venous thromboembolism. Atherosclerosis 2012;220:184–8.

[39] Enga KF, Brækkan SK, Hansen-Krone IJ, et al. Cigarette smoking and the risk of venous thromboembolism: the Tromsø Study. J Thromb Haemost 2012;10:2068–74.

[40] Brækkan SK, Hald EM, Mathiesen EB, et al. Competing risk of atherosclerotic risk factors for arterial and venous thrombosis in a general population: the Tromsø Study. Arterioscler Thromb Vasc Biol 2012;32:487–91.

[41] Marcucci R, Liotta AA, Cellai AP, et al. Increased plasma levels of factor VII levels in diabetic and normal subjects. Diabetologia 1980;64:172–3.

[42] Manfredini R, Gallerani M, Bosari B, et al. Seasonal variation in onset of pulmonary embolism is independent of patients’ underlying risk comorbid conditions. Clin Appl Thromb Hemost 2004;10:38–43.

[43] Ray JG, Lonn E, Yi Q, et al. Venous thromboembolism in association with features of the metabolic syndrome. J Q Med 2007;100:679–84.

[44] Yoo IH, De Paiva SA, Silvaeva LV, et al. Logistic regression analysis of potential prognostic factors for pulmonary thromboembolism. Chest 2003;123:813–21.

[45] Goldhaber SB, Savage DD, Garrison RJ, et al. Risk factors for pulmonary embolism: the Framingham study. Am J Med 1983;74:1023–8.

[46] Whitman MK, Cui Y, Flaws JA, et al. Low fibrinogen level: a predisposing factor for venous thromboembolic events with hormone replacement therapy. Am J Hematol 1999;61:271–3.

[47] Beaumont V, Lemort N, Beaumont JL. Oral contraceptives, sex steroidinduced antibodies and vascular abnormalities of venous thrombosis: results from 1338 cases. Eur Heart J 1991;12:1219–24.

[48] Godland IF, Winkler U, Lidegaard O, et al. Oclusive vascular diseases in oral contraceptive users. Epidemiology, pathophysiology and mechanisms. Drugs 2000;60:721–609.

[49] Lidegaard O. Smoking and use of oral contraceptives: impact on thrombotic diseases. Am J Obstet Gynecol 1999;180:S357–63.

[50] Goldhaber SZ, Grodstein F, Stampfer MJ, et al. A prospective study of risk factors for pulmonary embolism in women. JAMA 1997;277:642–5.

[51] Fronen A, Criqui MH, Denenberg J, et al. Common femoral vein dimensions and hemodynamics including Valsalva response as a function of sex, age, and ethnicity in a population study. J Vasc Surg 2001;33:1050–6.

[52] Sugerman H, Windsor A, Bessos M, et al. Intra-abdominal pressure, sagittal abdominal diameter and obesity comorbidity. J Intern Med 1997;241:71–9.

[53] Hajer GR, van Haeften TW, Visseren FL. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J 2008;29:2959–71.

[54] Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006;444:881–7.

[55] Finucane MM, Stevens GA, Cowan MJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 2011;377:557–67.

[56] Ageno W, Piantanida E, Dentali F, et al. Body mass index is associated with the development of the post-thrombotic syndrome. Thromb Haemost 2003;89:305–9.

[57] Larsen TE, Sørensen HT, Gislum M, et al. Maternal smoking, obesity, and risk of venous thromboembolism during pregnancy and the puerperium: a population-based case-control study. Thromb Res 2007;120:505–9.

[58] Jacobsen AF, Skjødestad FE, Sandset PM. Ante- and postnatal risk factors of venous thrombosis: a hospital-based case-control study. J Thromb Haemost 2008;6:903–12.

[59] Gary T, Hafer N, Froehlich H, et al. High factor VIII activity, high plasminogen activator inhibitor 1 antigen levels and low factor XII activity contribute to a thrombophilic tendency in elderly venous thromboembolism patients. Acta Haemtol 2010;124:217–7.

[60] Ageno W, Prandoni P, Romualdi E, et al. The metabolic syndrome and the risk of venous thrombosis: a case-control study. J Thromb Haemost 2006;4:1914–8.

[61] Cerello A, Giugliano D, Quattraro A, et al. Blood glucose may condition factor VII levels in diabetic and normal subjects. Diabetologia 1988;31:889–91.

[62] Stegenga ME, van der Crabben SN, Blümmer RM, et al. Hyperglycemia enhances coagulation and reduces neutrophil degranulation, whereas hyperinsulinaemia inhibits fibrinolysis during human endotoxemia. Blood 2008;112:82–9.

[63] Langouche L, Meersseman W, Vander Perre S, et al. Effect of insulin therapy on coagulation and fibrinolysis in medical intensive care patients. Crit Care Med 2008;36:1475–80.

[64] Marcucci R, Liotta AA, Celais AP, et al. Increased plasma levels of lipoprotein(a) and the risk of idiopathic and recurrent venous thromboembolism. Am J Med 2003;115:601–5.

[65] von Depka M, Nowak-Götti U, ESSERT R, et al. Increased lipoprotein(a) levels as an independent risk factor for venous thromboembolism. Blood 2000;96:3364–8.

[66] Lee KW, Lip GY. Effects of lifestyle on hemostasis, fibrinolysis, and platelet reactivity: a systematic review. Arch Intern Med 2003;163:2368–92.

[67] Miller GJ, Bauer KA, Cooper JA, et al. Activation of the coagulant pathway in cigarette smokers. Thromb Haemost 1998;79:549–53.

[68] Yarnell JW, Sweetnam PM, Rumley A, et al. Lifestyle and hemostatic risk factors for ischemic heart disease: the Caerphilly Study. Arterioscler Thromb Vasc Biol 2000;20:271–9.

[69] Oger E, Lacut K, Van Dreden P, et al. High plasma concentration of factor VIII coagulant is also a risk factor for venous thromboembolism in the elderly. Haematologica 2003;88:465.

[70] Feher MD, Rampling MW, Brown J, et al. Acute changes in atherogenic and thrombogenic factors with cessation of smoking. J R Soc Med 1990;83:146–8.

[71] Bakhti A, Erlinger TP. Smoking cessation and cardiovascular disease risk factors: results from the Third National Health and Nutrition Examination Survey. PLoS Med 2005;2:e160.

[72] Yarnell JW, Sweetnam PM, Rumley A, et al. Lifestyle factors and coagulation activation markers: the Caerphilly Study. Blood Coagul Fibrinolysis 2001;12:721–8.

[73] Zhao Z, Wang S, Ma W, et al. Diabetes mellitus increases the incidence of deep vein thrombosis after total knee arthroplasty. Arch Orthop Trauma Surg 2014;134:79–83.

[74] Cohn DM, Hermanides J, DeVries JH, et al. Stress-induced hyperglycemia and venous thromboembolism following total hip or total knee arthroplasty. Thromb Haemost 2012;107:225–31.
[86] Yukizawa Y, Inaba Y, Watanabe S, et al. Association between venous thromboembolism and plasma levels of both soluble fibrin and plasminogen-activator inhibitor 1 in 170 patients undergoing total hip arthroplasty. Acta Orthop 2012;83:14–21.
[87] Ray J. Dyslipidemia, statins and venous thromboembolism: a potential risk factor and a potential treatment. Curr Opin Pulm Med 2003;9:378–84.
[88] Squizzato A, Galli M, Romualdi E, et al. Statins, fibrates, and venous thromboembolism: a meta-analysis. Eur Heart J 2010;31:1248–56.
[89] Squizzato A, Romualdi E, Agemo W. Why should statins prevent venous thromboembolism? A systematic literature search and a call for action. J Thromb Haemost 2006;4:1925–7.
[90] Biere-Rafi S, Hutten BA, Squizzato A, et al. Statin treatment and the risk of recurrent pulmonary embolism. Eur Heart J 2013;34:1800–6.
[91] Lassila R, Jula A, Pitkäniemi J, et al. The association of statin use with reduced incidence of venous thromboembolism: a population-based cohort study. BMJ Open 2014;4:e005862.